Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Fibrotic, and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CMA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CMA1 Recombinant Protein / Active Serine Protease High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CMA1 Products |
| Gene Delivery | CMA1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View CMA1 Products |
| Benchmark Ab | Anti-CMA1 Recombinant Antibody Recombinant positive control for neutralization and ELISA development. |
View CMA1 Products |
| Validator | CMA1 siRNA Set For knockdown verification and functional assay validation. |
View CMA1 Products |
| Related Target A | ACE Angiotensin-Converting Enzyme; operates in parallel with CMA1 in the RAAS pathway. |
View ACE Products |
| Related Target B | TGFB1 Transforming Growth Factor Beta 1; downstream effector activated by chymase cleavage. |
View TGFB1 Products |
| Related Target C | TPSAB1 Tryptase; co-released with chymase from secretory granules during mast cell activation. |
View TPSAB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Cyno vs. Rodent) | Human, Cynomolgus, and Rodent CMA1 ortholog proteins available with >95% purity to assess species-specific inhibitor potency. |
| Subfamily counter screening (Chymotrypsin/Cathepsin G) | Homolog panel proteins strictly verified by mass spectrometry to exclude off-target serine protease inhibition. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity checks and target knockdown comparison. |
Live CMA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CMA1 therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective mast cell chymase inhibitors. As first-generation small molecule inhibitors reach clinical evaluation for cardiac and renal fibrosis, the next wave of R&D is targeting localized delivery and antibody-mediated neutralization to minimize systemic off-target profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Bayer, Shionogi, Sanofi | Heart Failure, CKD, Atopic Dermatitis | Selectivity Assay (Need Mutant vs WT Proteins & Homolog Panels) |
| Monoclonal Antibody | Academic Institutions, Biotech | Pulmonary Fibrosis, Asthma | Neutralization Validation (Need Glycosylated, Native-like HEK293 CMA1) |
| RNA Therapeutics | Preclinical consortia | Keloids, Localized Fibrosis | Knockdown Verification (Need high-efficiency siRNA & Lentivirus controls) |